BREAKING
162d 20h ago

Fortune: Insider Leaks Drove MEI Pharma’s Pre-Announcement Stock Spike Ahead of $100M Ethereum (ETH) Treasury Move

ETH

ETH/USDT

$2,113.64
-7.22%
24h Volume

$37,939,871,804.04

24h H/L

$2,293.99 / $2,068.20

Change: $225.79 (10.92%)

Long/Short
79.4%
Long: 79.4%Short: 20.6%
Funding Rate

+0.0040%

Longs pay

Data provided by COINOTAG DATALive data
Ethereum
Ethereum
Daily

$2,087.22

-2.84%

Volume (24h): -

Resistance Levels
Resistance 3$2,820.15
Resistance 2$2,294.17
Resistance 1$2,149.26
Price$2,087.22
Support 1$2,068.20
Support 2$1,940.12
Support 3$1,532.78
Pivot (PP):$2,109.73
Trend:Downtrend
RSI (14):22.5

Fortune reported that cancer drug developer MEI Pharma initiated a $100 million crypto treasury strategy in mid-July. In the days preceding the disclosure, MEI Pharma’s share price nearly doubled despite no new SEC filings, press releases, or notable social-media activity, raising questions about information flow ahead of the public announcement.

The investigation identified comparable pre-announcement surges at several small-cap issuers, including Kindly MD, Empery Digital, Fundamental Global, 180 Life Sciences, VivoPower, and Sonnet BioTherapeutics; spokespeople either declined to comment or did not respond, underscoring concerns about potential insider information and market leakage in connection with crypto-related corporate disclosures.

Some gains accrued to parties linked to the issuers rather than retail investors. ETH treasury company SharpLink saw its stock rise from $3 to over $6 in three trading days before its announcement, without SEC filings or press releases. A CEO of a crypto fund observed: “There was definitely leakage because they had contact with too many investors, so it was hard to control.”

Share News:
Don't Miss Breaking News